Search Bar & Filters
Found 12 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating the long-term safety and effects of the medicine ritlecitinib in children with severe alopecia areata, a condition that causes significant hair loss. This Phase 3 study involves participants who have completed previous pediatric studies on ritlecitinib and aims to assess the drugs safety, tolerability, and effectiveness over an extended period. Participants will take ritlecitinib capsules by mouth once daily at home. Those who received different doses in prior studies will continue with the same dose or be randomly assigned to higher or lower doses in this trial. The study lasts up to 3 years, during which participants may be switched to placebo if they do not meet treatment continuation criteria. Throughout the study, participants will attend 17 clinic visits and receive monthly phone calls for monitoring. Researchers will evaluate safety by tracking side effects and serious adverse events. Effectiveness will be measured using tools like the Severity of Alopecia Tool SALT scores, eyebrow and eyelash assessments, and various patient-reported outcomes. Assessments will occur regularly to observe changes and impacts on quality of life.
Actively Recruiting
Researchers are evaluating the safety and efficacy of GIA632 in adults aged 18 to 99 years with non-segmental vitiligo NSV. This randomized, double-blind, placebo-controlled Phase 2b study aims to identify the optimal dose of GIA632 to be further studied in a Phase 3 program. The study also includes an extension period to assess longer-term safety and effectiveness. Participants will be randomly assigned to one of several groups receiving either GIA632 or a placebo during a 48-week core treatment period. The study will measure the dose-response relationship of GIA632 and compare its effects with placebo. The extension phase will further evaluate the safety and efficacy over a longer term. During the study, participants will have regular assessments including measurement of facial and total body vitiligo area using the Vitiligo Area Scoring Index VASI at baseline and multiple time points up to 48 weeks. Researchers will also track improvements using the Vitiligo Noticeability Scale. Safety and treatment response will be monitored throughout the study period, which lasts up to approximately four years including follow-up.
Actively Recruiting
Researchers are studying the safety and effectiveness of GIA632 in people with moderate to severe cutaneous lichen planus cLP. The goal is to find the best dose of GIA632 to use in future larger studies. This is a Phase IIb trial that includes multiple dosing regimens and compares GIA632 with placebo. Participants will be randomly assigned to receive either GIA632 at one of several dose levels or a matching placebo during a 16-week double-blind treatment period. After this core period, participants can continue in a 52-week extension phase to further assess safety and effects. Finally, there is a 12-week safety follow-up period after treatment ends. During the study, participants will be assessed regularly using the Investigator Global Assessment IGA scale, peak itch rating scales, and Lichen Planus Activity and Damage Index LiPADI scores. Safety will be monitored through adverse event reports for up to 80 weeks. The total study duration includes screening, treatment, extension, and follow-up phases lasting over a year.
Actively Recruiting
This research aims to evaluate the safety and effectiveness of ELAPR002f injectable gel in adults with moderate to severe atrophic acne scars. These scars are flat or indented marks that remain after acne heals and can affect quality of life through reduced self-esteem and embarrassment. The study is a controlled, randomized trial including about 395 adults with scarring on both cheeks, conducted at multiple sites in the United States. Participants are divided into two cohorts. Cohort 1 receives ELAPR002f injectable gel openly, while Cohort 2 participants are randomly assigned to receive either ELAPR002f gel or a saline control via intradermal injections. Treatments are given on Days 1, 31, and 61. After the three treatment sessions over two months, participants are followed for up to 12 months to observe outcomes and any side effects. During the study, participants will have regular visits at a clinic or hospital for medical assessments, blood tests, and questionnaires to monitor their progress and any side effects. Researchers will measure the percentage of participants who achieve at least a 20% reduction in acne scar area and various safety parameters, including injection site responses and changes in vital signs and laboratory values. The total study duration for each participant can be up to 420 days.
Actively Recruiting
Researchers are evaluating remibrutinib in adult participants with severe chronic pruritus of unknown origin CPUO, a condition causing persistent severe itching without a known cause. This phase 3, global, randomized, double-blind, placebo-controlled study aims to assess the efficacy, safety, and tolerability of remibrutinib for this condition. Participants will undergo up to 60 weeks of study divided into four periods. After a screening period of up to 4 weeks, participants enter a 24-week double-blind phase receiving either remibrutinib or placebo. Then, a 28-week open-label phase follows, where all participants receive remibrutinib. Lastly, there is a 4-week treatment-free safety follow-up period. Throughout the study, participants will be regularly assessed for itch severity using the Worst Itch Numerical Rating Scale and Patient Global Impression of Severity. Researchers will monitor sleep disturbance related to itching, record adverse events, and evaluate treatment tolerability. The entire participation can last up to 60 weeks, including treatment and follow-up phases.
Actively Recruiting
Healthy Volunteer
Researchers are conducting a phase 3 clinical trial to study adults with moderate or severe abdominal subcutaneous fat. The trial aims to evaluate the efficacy, safety, and tolerability of CBL-514 injection compared to a placebo in reducing abdominal fat. Approximately 320 participants will be enrolled to better understand how well this treatment works and how safe it is for reducing fat under the skin in the abdominal area. Participants will be randomly assigned to receive either the CBL-514 injection or a placebo 0.9% Sodium Chloride solution. Each participant can receive up to four treatments, with injections administered subcutaneously to the abdomen at four-week intervals. Both groups will receive up to 120 mL per treatment, delivered through 50 injections each time. During the study, participants will undergo assessments including patient and clinician reports on abdominal fat levels, measured from the start of the study to four weeks after the final treatment. Researchers will monitor changes in abdominal fat and improvements on rating scales. Participants will also be evaluated for safety and tolerability throughout the trial, which is expected to last until September 2027.
Actively Recruiting
Researchers are evaluating the effectiveness of adding the drug tirzepatide to ongoing ixekizumab therapy in adults with moderate-to-severe plaque psoriasis who are also overweight or obese with at least one weight-related health condition. This Phase 4 study aims to assess how well this combination works in real-world clinical practice over a period of up to 12 months. Participants will continue their prescribed ixekizumab treatment and start taking tirzepatide through subcutaneous injections according to approved guidelines. The study is designed as a single-arm, open-label trial where all participants receive tirzepatide along with ixekizumab. The treatment period covers about one year, during which the response to this combined therapy will be closely observed. Throughout the study, participants will undergo regular assessments to measure improvements in their skin condition and weight. Key outcomes include the percentage achieving minimal impact on quality of life related to dermatology and at least 10% weight loss after 12 months. Additional evaluations at 6 and 12 months will monitor skin involvement, global physician and patient assessments, and weight changes. Safety and tolerability will also be followed during this time.
Actively Recruiting
The trial investigates the use of YCANTH VP-102TO-208 for treating common warts in children and adults aged 2 years and older. This Phase 3 study is double-blind, randomized, and vehicle-controlled, aiming to evaluate the safety and effectiveness of YCANTH compared to a placebo vehicle. Common warts caused by the human papilloma virus HPV are the focus, excluding certain wart types and locations. Participants receive topical applications of either YCANTH or a placebo vehicle every 21 days for up to four treatments during a 75-day period. The treated warts are covered with occlusive tape overnight following the application. Treatment may be delayed if temporary local skin reactions occur, and participants must attend all scheduled treatment and follow-up visits regardless of wart clearance. In Japan, participants completing this study may join a long-term follow-up study for up to 54 weeks to monitor safety and efficacy. Participants undergo wart measurements, dermatologic exams, and evaluation of treatment responses during visits. Follow-up includes in-person visits and phone calls to assess clearance and monitor adverse events. Researchers measure the proportion of participants achieving complete wart clearance at Day 84 and monitor safety through adverse event reporting and skin reaction assessments. The total participant involvement spans screening, treatment, and follow-up periods totaling several months.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of a new formulation of Levulan Kerastick combined with photodynamic therapy PDT to treat actinic keratosis AK on the upper arms. This Phase 3, randomized, multi-center, and evaluator-blind study compares this treatment to a vehicle control in adults with mild to moderate AK lesions. The goal is to see how well the treatment clears the lesions and to assess its safety. Participants will be randomly assigned to receive either the Levulan Kerastick solution or a vehicle solution applied to the skin, followed by an incubation period under occlusion and exposure to blue light using a specialized device. Up to two PDT sessions may be given depending on how well lesions clear. The study includes multiple time points for assessing lesion clearance, cosmetic outcomes, patient satisfaction, and recurrence rates. Throughout the study, participants will be monitored through visits where the skin lesions are evaluated, safety assessments are made including skin reactions and lab tests, and patient feedback is collected. The primary outcome focuses on the complete clearance rate of AK lesions at Week 12. Secondary outcomes involve lesion clearance at various weeks up to 24, cosmetic responses, and recurrence. The total study duration includes treatment and follow-up assessments extending to Week 24.
1-10 of 12
1